Recombinant human CDA protein (His tag N-Terminus)

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytidine deaminase (CDA) also known as CDD is a zinc-dependent enzyme responsible for deaminating cytidine. The full form of CDA has a molecular mass of approximately 41 kDa. CDA is widely expressed in various tissues including liver kidney and leukocytes. It plays an important role in nucleotide metabolism by converting cytidine to uridine and 2'-deoxycytidine to 2'-deoxyuridine which impacts nucleic acid stability and synthesis. Researchers frequently use techniques such as ELISA and Western blotting to study CDA expression and activity often referencing it in contexts like "CDA Western" or "57 seconds CDA."

Biological function summary

CDA enzyme influences the pyrimidine salvage pathway by facilitating nucleotide degradation and recycling. It operates independently rather than as part of a protein complex. The activity of this enzyme ensures a balanced nucleotide pool essential for DNA replication and repair processes. This balance affects cellular proliferation and survival highlighting the importance of studying CDA protein in normal physiology and various pathological conditions.

Pathways

CDA contributes significantly to pyrimidine metabolism and its recycling pathway. It maintains a connection with ribonucleotide reductase which plays a role in the regulation of deoxyribonucleotide pools during DNA synthesis. This interplay highlights the enzyme’s involvement in DNA repair pathways ensuring proper cell division and genomic integrity. Within these pathways enzymes like cytidine triphosphate synthetase also relate to CDA by participating in nucleotide homeostasis.

Improper CDA function is linked to specific cancers including acute myeloid leukemia due to altered nucleotide metabolism leading to genomic instability. The enzyme's activity also affects the pharmacokinetics of cytidine analogues like gemcitabine used in cancer treatment. CDA overexpression might result in reduced drug efficacy thereby hindering therapy in affected patients. Connections exist between CDA and proteins involved in chemoresistance such as ribonucleotide reductase showing its significance in treatment outcomes.